Roche Holding (SWX:ROP) Reports Phase III Vamikibart Data In Uveitic Macular Edema

What happened: Genentech, part of Roche Holding (SWX:ROP), reported new Phase III results for vamikibart in uveitic macular edema (UME). The FDA has accepted a Biologics License Application for vamikibart in UME. Key numbers: FDA decision currently scheduled for 2027. CHF370 fair value cited for Roche Holding. Why it matters: The data suggest vamikibart could become the first non steroid targeted therapy option for this severe cause of vision loss. UME is a smaller indication than AMD or diabetic macular edema, and rivals such as Novartis and Regeneron already contest adjacent segments.

Genentech, part of Roche Holding (SWX:ROP), reported new Phase III results for vamikibart in uveitic macular edema (UME). The FDA has accepted a Biologics License Application for vamikibart in UME.

The data suggest vamikibart could become the first non steroid targeted therapy option for this severe cause of vision loss. UME is a smaller indication than AMD or diabetic macular edema, and rivals such as Novartis and Regeneron already contest adjacent segments.